Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Additional Genomics Services
      • Sanger Sequencing
      • Array Analysis
      • Next-Generation Sequencing (NGS)
  • Labs
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
      • Lab Members
    • Fernandez-Godino Lab
      • Lab Members
      • Macular Degeneration
      • Publications
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • News
  • Recent OGI Publications

Featured Posts

  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder

Recent Posts

  • Precision Medicine at Work
  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Ocular Genomics Institute Scientists publish large Gene-Wide Association Study of Glaucoma
  • AAVCOVID Vaccine developed by Luk Vandenberghe to start Clinical trials

Archives

  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication
  • Uncategorized

Recent OGI Publications
June 12, 2020

AAV-Mediated Gene Augmentation Therapy Restores Critical Functions in Mutant PRPF31+/− iPSC-Derived RPE Cells

Elizabeth M. Brydon13Revital Bronstein13Adriana Buskin2Majlinda Lako2Eric A. Pierce1Rosario Fernandez-Godino1

Mutations in the PRPF31 gene account for 10% of dominant retinitis pigmentosa (RP), which is the most common kind of inherited blindness.

This publication uses retinal cells derived from induced pluripotent stem cells as a proof-of-concept that AAV-based gene therapy can be used for treatment of PRPF31-associated RP.

Expanding the phenotypic spectrum in RDH12-associated retinal disease

Scott HA, Place EM, Ferenchak K, Zampaglione E, Wagner NE, Chao KR, DiTroia SP, Navarro-Gomez D, Mukai S, Huckfeldt RM, Pierce EA, Bujakowska KM. Cold Spring Harb Mol Case Stud. 2020 Feb 3;6(1). pii: a004754. doi: 10.1101/mcs.a004754. Print 2020 Feb.

Our recent paper “Expanding the phenotypic spectrum of RDH12-associated retinal disease” describes eleven inherited retinal degeneration (IRD) patients with bi-allelic mutations in RDH12 that display a range of phenotypic severity. 

Traditionally mutations in RDH12 were only screened in severe cases of IRD potentially missing patients with milder disease, however broad genetic testing allowed the diagnosis of two patients with macular dystrophy in this study.  Given the wide phenotypic spectrum of RDH12 disease, we advocate for more robust approach with targeted panel testing of all known IRD genes to provide accurate genetic diagnosis.

In addition, we describe 15 causal alleles including four novel variants that contribute to the catalog of RDH12 mutations to aid in genetic diagnosis of RDH12-associated retinal disease.

Copy-number variation contributes 9% of pathogenicity in the inherited retinal degenerations.

Zampaglione E, Kinde B, Place EM, Navarro-Gomez D, Maher M, Jamshidi F, Nassiri S, Mazzone JA, Finn C, Schlegel D, Comander J, Pierce EA, Bujakowska KM.Genet Med. 2020 Feb 10. doi: 10.1038/s41436-020-0759-8. [Epub ahead of print]

In this study, we showed that some previously unsolved inherited retinal disease (IRD) cases were caused by copy number variations (CNVs) in the known genes.

We analyzed a cohort of 500 IRD patients, solving 55.6% of the cases with an initial single nucleotide variant (SNV) analysis. We then looked for potentially causal CNVs, comparing three methods: two sequencing based prediction algorithms, gCNV and ExomeDepth, and a more conventional SNP-array based method.

We found that of the three approaches, gCNV performed the best, and that adding CNV analysis to our pipeline improved our IRD solving rate by 10.2%.

Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

  • Engle Lab
  • Pierce Lab
  • Vandenberghe Lab
  • Wiggs Lab
  • Genomics Core Lab
  • Functional Genomics Core (Zebrafish Facility)
  • MEEI Bioinformatics Center (MBC)

Sitemap

  • Affiliates
  • Careers
  • Meet the Team
  • News & publications
  • Support Our Research
  • Services
  • Privacy
website-boston WebsiteBoston